Univariate analysis of risk factors for cGVHD development
| . | Univariate analysis . | ||||
|---|---|---|---|---|---|
| No. of cases . | Events . | Probability, % . | (95% CI) . | P . | |
| Patient age | |||||
| Younger than 2 y | 108 | 9 | 9 | (3-14) | .0001 |
| 2-5 y | 122 | 27 | 14 | (16-31) | |
| 5-10 y | 239 | 67 | 30 | (24-36) | |
| 10-15 y | 170 | 46 | 29 | (22-37) | |
| 15 y or older | 57 | 24 | 44 | (31-58) | |
| Donor age | |||||
| Younger than 2 y | 49 | 2 | 4 | (0-10) | .0002 |
| 2-5 y | 84 | 8 | 10 | (3-16) | |
| 5-10 y | 139 | 32 | 25 | (17-32) | |
| 10-15 y | 100 | 26 | 27 | (18-36) | |
| 15-20 y | 75 | 21 | 30 | (19-40) | |
| 20-30 y | 96 | 30 | 36 | (25-46) | |
| 30-40 y | 96 | 31 | 39 | (29-49) | |
| 40 y or older | 49 | 19 | 42 | (27-57) | |
| Unknown | 8 | 4 | |||
| Sex | |||||
| Female donor and male recipient | 196 | 62 | 34 | (27-41) | .01 |
| Other | 497 | 109 | 23 | (20-27) | |
| Unknown | 3 | 2 | |||
| Parity* | |||||
| Female donor, no pregnancy | 34 | 18 | 58 | (40-76) | NS |
| Female donor, 1 or more pregnancies | 37 | 15 | 44 | (27-61) | |
| Diagnosis | |||||
| Nonmalignant disease | 246 | 31 | 13 | (9-17) | .001 |
| Malignant disease | 450 | 142 | 35 | (30-39) | |
| Donor | |||||
| HLA-identical family | 461 | 105 | 24 | (20-28) | .019 |
| Partially matched family | 68 | 15 | 27 | (15-39) | |
| HLA-identical unrelated | 141 | 48 | 37 | (29-46) | |
| Partially matched unrelated | 26 | 5 | 20 | (4-35) | |
| Stem cell source | |||||
| Bone marrow | 647 | 168 | 28 | (24-31) | .027 |
| Peripheral blood | 17 | 4 | 30 | (4-55) | |
| Cord blood | 32 | 1 | 3 | (0-9) | |
| Stem cell source | |||||
| Bone marrow + peripheral blood | 664 | 172 | 28 | (24-31) | .0073 |
| Cord blood | 32 | 1 | 3 | (0-9) | |
| Conditioning regimen | |||||
| Chemotherapy based | 369 | 60 | 17 | (13-21) | .0001 |
| TBI based | 327 | 113 | 38 | (33-44) | |
| GVHD prophylaxis | |||||
| Cs-A | 348 | 82 | 25 | (20-30) | .0052 |
| Cs-A + MTX | 129 | 32 | 27 | (19-35) | |
| Cs-A + PDN | 63 | 13 | 23 | (12-34) | |
| Cs-A + MTX + ALG or mAb | 104 | 39 | 42 | (31-42) | |
| Cs-A + ALG or mAb ± PDN | 33 | 4 | 15 | (1-29) | |
| T-cell depletion | 19 | 3 | 16 | (0-32) | |
| GVHD prophylaxis | |||||
| Cs-A + MTX + ALG or mAb | 104 | 39 | 42 | (31-52) | .0001 |
| Other prophylaxis | 592 | 134 | 24 | (21-28) | |
| Cell dose infused | |||||
| Less than 2 × 108/kg | 117 | 37 | 35 | (26-44) | .09 |
| 2 × 108/kg or more | 556 | 132 | 25 | (21-29) | |
| Unknown | 23 | 4 | |||
| Acute GVHD grade | |||||
| Grade 0-I | 406 | 54 | 14 | (11-18) | .0001 |
| Grade II-IV | 290 | 119 | 45 | (39-51) | |
| . | Univariate analysis . | ||||
|---|---|---|---|---|---|
| No. of cases . | Events . | Probability, % . | (95% CI) . | P . | |
| Patient age | |||||
| Younger than 2 y | 108 | 9 | 9 | (3-14) | .0001 |
| 2-5 y | 122 | 27 | 14 | (16-31) | |
| 5-10 y | 239 | 67 | 30 | (24-36) | |
| 10-15 y | 170 | 46 | 29 | (22-37) | |
| 15 y or older | 57 | 24 | 44 | (31-58) | |
| Donor age | |||||
| Younger than 2 y | 49 | 2 | 4 | (0-10) | .0002 |
| 2-5 y | 84 | 8 | 10 | (3-16) | |
| 5-10 y | 139 | 32 | 25 | (17-32) | |
| 10-15 y | 100 | 26 | 27 | (18-36) | |
| 15-20 y | 75 | 21 | 30 | (19-40) | |
| 20-30 y | 96 | 30 | 36 | (25-46) | |
| 30-40 y | 96 | 31 | 39 | (29-49) | |
| 40 y or older | 49 | 19 | 42 | (27-57) | |
| Unknown | 8 | 4 | |||
| Sex | |||||
| Female donor and male recipient | 196 | 62 | 34 | (27-41) | .01 |
| Other | 497 | 109 | 23 | (20-27) | |
| Unknown | 3 | 2 | |||
| Parity* | |||||
| Female donor, no pregnancy | 34 | 18 | 58 | (40-76) | NS |
| Female donor, 1 or more pregnancies | 37 | 15 | 44 | (27-61) | |
| Diagnosis | |||||
| Nonmalignant disease | 246 | 31 | 13 | (9-17) | .001 |
| Malignant disease | 450 | 142 | 35 | (30-39) | |
| Donor | |||||
| HLA-identical family | 461 | 105 | 24 | (20-28) | .019 |
| Partially matched family | 68 | 15 | 27 | (15-39) | |
| HLA-identical unrelated | 141 | 48 | 37 | (29-46) | |
| Partially matched unrelated | 26 | 5 | 20 | (4-35) | |
| Stem cell source | |||||
| Bone marrow | 647 | 168 | 28 | (24-31) | .027 |
| Peripheral blood | 17 | 4 | 30 | (4-55) | |
| Cord blood | 32 | 1 | 3 | (0-9) | |
| Stem cell source | |||||
| Bone marrow + peripheral blood | 664 | 172 | 28 | (24-31) | .0073 |
| Cord blood | 32 | 1 | 3 | (0-9) | |
| Conditioning regimen | |||||
| Chemotherapy based | 369 | 60 | 17 | (13-21) | .0001 |
| TBI based | 327 | 113 | 38 | (33-44) | |
| GVHD prophylaxis | |||||
| Cs-A | 348 | 82 | 25 | (20-30) | .0052 |
| Cs-A + MTX | 129 | 32 | 27 | (19-35) | |
| Cs-A + PDN | 63 | 13 | 23 | (12-34) | |
| Cs-A + MTX + ALG or mAb | 104 | 39 | 42 | (31-42) | |
| Cs-A + ALG or mAb ± PDN | 33 | 4 | 15 | (1-29) | |
| T-cell depletion | 19 | 3 | 16 | (0-32) | |
| GVHD prophylaxis | |||||
| Cs-A + MTX + ALG or mAb | 104 | 39 | 42 | (31-52) | .0001 |
| Other prophylaxis | 592 | 134 | 24 | (21-28) | |
| Cell dose infused | |||||
| Less than 2 × 108/kg | 117 | 37 | 35 | (26-44) | .09 |
| 2 × 108/kg or more | 556 | 132 | 25 | (21-29) | |
| Unknown | 23 | 4 | |||
| Acute GVHD grade | |||||
| Grade 0-I | 406 | 54 | 14 | (11-18) | .0001 |
| Grade II-IV | 290 | 119 | 45 | (39-51) | |
The impact of parity on cGVHD occurrence was evaluated in the 117 donor-recipient pairs with a female donor older than 20 years; data on parity were available for 71 of these 117 donors (61%).